真实世界环境中接受恩扎卢胺治疗的初治转移性去势抵抗性前列腺癌黑人与白人男性的前列腺特异性抗原应答与临床无进展生存期
这项回顾性队列研究基于IntrinsiQ Specialty Solutions™数据库2014至2018年数据,纳入214例黑人和1332例白人初治转移性去势抵抗性前列腺癌患者,比较恩扎卢胺治疗后的PSA应答与临床无进展生存期。多变量分析显示两种族PSA应答≥50%下降风险相似,黑人男性临床无进展生存期显著更优(HR 0.82;95%CI 0.68-0.98;P=0.03)。
要点
- 黑人男性与白人男性在恩扎卢胺治疗后PSA应答≥50%下降的风险相似。
- 黑人男性临床无进展生存期显著优于白人男性(HR 0.82;95%CI 0.68-0.98;P=0.03)。
- 黑人男性PSA下降≥90%的比例呈数值上更高的趋势(HR 1.23;95%CI 0.93-1.62;P=0.14)。
核心结论
- 在推测为初治转移性去势抵抗性前列腺癌的患者中,黑人与白人男性接受恩扎卢胺治疗的PSA应答相似,但黑人男性的临床无进展生存期优于白人男性。
- 作者指出需要进一步研究来验证这些发现。
研究设计与样本
- 回顾性队列研究,数据来自IntrinsiQ Specialty Solutions™数据库,该数据库收集社区泌尿外科实践的电子病历。
- 纳入2014年至2018年启动恩扎卢胺治疗的前列腺癌患者,以首次处方恩扎卢胺的日期作为索引日期,并以此替代转移性去势抵抗性前列腺癌的诊断。
- 排除接受过化疗和/或阿比特龙治疗的患者。
- 研究共纳入214例黑人男性和1332例白人男性初治前列腺癌患者,根据研究期间恩扎卢胺的适应证推测为转移性去势抵抗性前列腺癌。
- 使用Kaplan-Meier法和校正基线特征的Cox模型按种族估计PSA应答和临床无进展生存期。
主要发现
- 黑人男性比白人男性更年轻,且基线中位PSA水平更高。
- 恩扎卢胺治疗持续时间、随访时间和索引后PSA检测次数在种族间相似。
- 在多变量分析中,患者达到PSA下降≥50%的风险相似。
- 黑人男性PSA下降≥90%呈数值上更高的趋势(HR 1.23;95%CI 0.93-1.62;P=0.14)。
- 在多变量分析中,黑人男性的临床无进展生存期显著更优(HR 0.82;95%CI 0.68-0.98;P=0.03)。
关键数值与推荐
- PSA下降≥50%的风险:黑人与白人男性相似。
- PSA下降≥90%:黑人男性HR 1.23(95%CI 0.93-1.62;P=0.14),呈数值上更高的趋势。
- 临床无进展生存期:黑人男性HR 0.82(95%CI 0.68-0.98;P=0.03),显著优于白人男性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要进一步研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the United States, Black men have a higher incidence of prostate cancer (PC)-related mortality than men of other races. Several real-world studies in advanced PC suggest, however, that Black men respond better to novel hormonal therapies than White men. Data on treatment responses to enzalutamide by race are limited. We assessed real-world prostate-specific antigen (PSA) response and clinical progression-free survival (cPFS) of Black vs. White men with chemotherapy-naïve PC treated with enzalutamide. METHODS: This retrospective cohort study included patients with PC who initiated enzalutamide treatment from 2014 to 2018 in the IntrinsiQ Specialty Solutions™ database, a collection of electronic medical records from community urology practices. Index date was the date of the first prescription for enzalutamide, used as a proxy for metastatic castration-resistant PC (mCRPC). Patients who had undergone chemotherapy and/or abiraterone therapy were excluded. Kaplan-Meier and Cox models adjusted for baseline characteristics were used to estimate PSA response and cPFS by race. RESULTS: The study included 214 Black and 1332 White men with chemotherapy-naïve PC presumed to have mCRPC based on the enzalutamide indication during the study period. Black men were younger and had higher baseline median PSA levels than White men. Enzalutamide therapy duration, follow-up time, and number of post-index PSA tests were similar between races. In multivariable analyses, the risk of patients achieving a ≥ 50% PSA decline was similar, whereas a numerically higher trend of ≥90% PSA decline was observed in Black men (HR 1.23; 95% CI 0.93-1.62 [P = 0.14]). In the multivariable analysis, Black men had significantly better cPFS (HR 0.82; 95% CI 0.68-0.98 [P = 0.03]). CONCLUSIONS: Black and White men with presumed chemotherapy-naïve mCRPC had similar PSA responses when treated with enzalutamide, but Black men had better cPFS than White men. Further research is warranted to validate these findings.
引用
- Freedland SJ, Hong A, El-Chaar N, et al. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting. Prostate Cancer Prostatic Dis. 2022. PMID: 36517634. doi:10.1038/s41391-022-00622-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。